AptarGroup Inc., an expert in consumer dispensing, active packaging, drug delivery solutions and services, has acquired all operating assets and the proprietary portfolio of Cohero Health Inc., a digital therapeutics company transforming respiratory disease management for asthma and chronic obstructive pulmonary disorder (COPD). 
 
Founded in 2013, New York-based Cohero Health develops innovative digital tools and technologies to improve respiratory care, reduce avoidable costs and optimize medication utilization.
 
“Cohero Health further strengthens and expands Aptar’s digital portfolio, in this case, with a focus in respiratory disease management,” commented Sai Shankar, Aptar Pharma’s vice president, Global Digital Healthcare Systems. “Aptar has made previous investments in digital respiratory company Sonmol in China and digital health company Navia Life Care in India. With this strategic bolt on, Aptar now has global capabilities to deploy digital respiratory health, utilizing either the Cohero or Aptar device portfolio/platform. The investment will also facilitate Aptar’s ability to provide diagnostic solutions in respiratory and a significant number of other disease categories.”
 
With this transaction, Aptar Pharma acquires Cohero Health’s turnkey digital health platform and device assets including:
 

• BreatheSmart Connect digital health platform – a care coordination and HIPAAcompliant SaaS cloud service which captures and securely stores data from Cohero Health’s devices and BreatheSmart software for remote monitoring and patient communications to help manage patient therapy;
• BreatheSmart App – designed for patient habit creating and behavior change, driving appropriate medication utilization. Provides real-time tracking of medication adherence and lung function, along with reminders, educational materials and symptom/trigger recording;
• HeroTracker Sensors – Bluetooth enabled medication smart inhaler sensors designed for both control and rescue medications. Attaches to respiratory medications to automatically record time and date of doses taken; and
• mSpirometer and cSpirometer lung function diagnostic sensors – enables comprehensive pulmonary lung function testing in a handheld wireless device.

 
Adding digital solutions to current treatments and therapies provides a mechanism for patients and health care providers to better manage disease conditions by providing seamless integration between disease management solutions and therapies. Patients benefit by having new tools at their disposal to stay on therapy, manage disease state and engage in more informed conversations with their health care providers. In addition, health care providers are able to better monitor their patients in real-time and make more informed decisions to improve standard of care.
 
“Cohero and Aptar are simply a great fit presenting a unique opportunity to leverage the complementary strengths of both companies. Building on our robust platform and rich innovations, we expect this combination to position us to lead the way in delivering on our joint vision, developing digital therapeutics that provide patients a better future and bring our customers stability and greater breadth of digital tools, actionable data, services and solutions,” said Joe Condurso, chief executive officer, Cohero Health, who will join Aptar Pharma. “I want to recognize and thank the Cohero Health team, and express deep gratitude to each of them for their many contributions over the years, which have enabled us to carry on the vision and mission to transform respiratory care.”